David Young's most recent trade in Processa Pharmaceuticals Inc was a trade of 17,272 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 17,272 | 222,677 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.41 per share. | 01 Apr 2025 | 5,345 | 217,332 | - | 0.4 | 2,202 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Purchase of securities on an exchange or from another person at price $ 0.80 per share. | 27 Jan 2025 | 124,500 | 205,405 | - | 0.8 | 99,289 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 124,500 | 124,500 | - | - | Warrants | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 62,250 | 62,250 | - | - | Warrants | |
| Avnet Inc. | Jay David Youngblood | SVP, Chief Digital Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.28 per share. | 03 Jan 2025 | 206 | 2,570 (0%) | 0% | 52.3 | 10,770 | Common Stock |
| Avnet Inc. | Jay David Youngblood | SVP, Chief Digital Officer | Grant, award, or other acquisition of securities at price $ 53.98 per share. | 21 Oct 2024 | 2,776 | 2,776 (0%) | 0% | 54.0 | 149,848 | Common Stock |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 31.88 per share. | 18 Sep 2024 | 3,920 | 18,877 (0%) | 0% | 31.9 | 124,970 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 3,233 | 21,922 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 2,425 | 24,347 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 1,675 | 81,061 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Apr 2024 | 644 | 81,187 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.79 per share. | 05 Apr 2024 | 518 | 80,543 | - | 2.8 | 1,445 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 404 | 24,751 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2024 | 404 | 25,155 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.71 per share. | 05 Apr 2024 | 282 | 80,905 | - | 1.7 | 482 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Purchase of securities on an exchange or from another person at price $ 2.45 per share. | 07 Feb 2024 | 21,000 | 79,387 | - | 2.5 | 51,526 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Purchase of securities on an exchange or from another person at price $ 2.53 per share. | 06 Feb 2024 | 20,000 | 58,387 | - | 2.5 | 50,504 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 1,675 | 19,333 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 1,675 | 81,062 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | David Young | Director, Pres. Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.79 per share. | 01 Jan 2024 | 518 | 80,544 | - | 2.8 | 1,445 | Common Stock |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 39.16 per share. | 20 Sep 2023 | 3,192 | 14,957 (0%) | 0% | 39.2 | 124,999 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.80 per share. | 12 Jun 2023 | 40,000 | 470,424 | - | 0.8 | 32,000 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.55 per share. | 14 Apr 2023 | 20,000 | 430,424 | - | 0.5 | 10,998 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.48 per share. | 11 Apr 2023 | 20,000 | 410,424 | - | 0.5 | 9,600 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.52 per share. | 11 Apr 2023 | 20,000 | 370,424 | - | 0.5 | 10,400 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.45 per share. | 11 Apr 2023 | 20,000 | 390,424 | - | 0.5 | 9,000 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.80 per share. | 09 Feb 2023 | 18,750 | 350,424 | - | 0.8 | 15,000 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 25,350 | 400,343 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 24,030 | 424,373 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 25,350 | 374,993 | - | - | Restricted Stock Units | |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Sep 2022 | 2,930 | 2,930 | - | - | Outside Director Stock Option (right to buy) | |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 42.40 per share. | 21 Sep 2022 | 1,415 | 11,765 (0%) | 0% | 42.4 | 59,996 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Aug 2022 | 9,250 | 377,784 | - | 0 | Common Stock | |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 7,601 | 389,565 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | David Young | Director, President & CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.17 per share. | 05 Aug 2022 | 2,531 | 387,034 | - | 3.2 | 8,023 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 46,877 | 349,643 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 247,841 | 302,766 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 6,024 | 6,024 | - | - | Restricted Stock Units | |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2021 | 4,420 | 4,420 | - | - | Outside Director stock option (right to buy) | |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 33.63 per share. | 22 Sep 2021 | 1,784 | 10,350 (0%) | 0% | 33.6 | 59,996 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2021 | 7,601 | 381,964 | - | - | Common Stock | |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2021 | 12,858 | 12,858 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2021 | 8,572 | 8,572 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2021 | 1,907 | 10,034 | - | - | Restricted Stock Units | |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.67 per share. | 23 Jun 2021 | 10,000 | 345,190 | - | 7.7 | 76,716 | Common Stock |
| Processa Pharmaceuticals Inc | David Young | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 8,127 | 8,127 | - | - | Restricted Stock Units | |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 8,434 | 8,434 | - | - | Outside Director stock option (right to buy) | |
| Scholastic Corp. | David J. Young | Director | Grant, award, or other acquisition of securities at price $ 20.48 per share. | 23 Sep 2020 | 2,636 | 8,566 (0%) | 0% | 20.5 | 53,985 | Common Stock |